ALT

Altimmune Inc

2.04

Oct 30 • 3:59 PM ET -0.10 (-4.67%)

2.06

Aftermarket • 7:31 PM ET +0.02 (0.97%)

Healthcare Biotechnology USA Small NASD

Peers: VKTX SGMT IVA GPCR MDGL KLRA GALT MBX MTVA AARD

| Held by: VTI IWM XBI VXF IWN FESM VTWO IBB VHT IWC

Scroll to Statements

Index	RUT
Market Cap	396.82M
Enterprise Value	106.52M
Income	-91.76M
Sales	0.03M
Book/sh	2.44
Cash/sh	1.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	57
IPO	Oct 06, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	13227.33
P/B	0.84
P/C	1.22
P/FCF	-
EV/EBITDA	-
EV/Sales	3550.67
Quick Ratio	26.77
Current Ratio	26.77
Debt/Eq	0.08
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-0.79
EPS next Y	-0.64
EPS next Q	-0.13
EPS this Y	41.80%
EPS next Y	-9.21%
EPS next 5Y	14.25%
EPS past 3/5Y	17.87% 12.17%
Sales past 3/5Y	- -65.33%
EPS Y/Y TTM	33.01%
Sales Y/Y TTM	55.00%
EPS Q/Q	54.71%
Sales Q/Q	-100.00%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	13.36% -

Insider Own	5.59%
Insider Trans	0.14%
Inst Own	72.44%
Inst Trans	34.37%
ROA	-25.58%
ROE	-28.87%
ROIC	-17.99%
Gross Margin	-219.35%
Oper. Margin	-320725.81%
Profit Margin	-296000.00%
SMA20	-12.24%
SMA50	-27.83%
SMA200	-37.85%
Trades

Shs Outstand	194.47M
Shs Float	183.64M
Short Float	23.00%
Short Ratio	10.38
Short Interest	42.23M
52W High	6.44 -68.32%
52W Low	2.00 2.26%
Volatility	5.95% 4.97%
ATR (14)	0.12
RSI (14)	26.67
Beta	0.11
Rel Volume	0.86
Avg Volume	4.07M
Volume	3,518,584

Perf Week	-3.77%
Perf Month	-26.09%
Perf Quarter	-32.00%
Perf Half Y	-27.66%
Perf YTD	-43.49%
Perf Year	-49.88%
Perf 3Y	-14.64%
Perf 5Y	-81.11%
Perf 10Y	-97.92%
Recom	1.30
Target Price	17.11
Prev Close	2.14
Price	2.04
Change %	-4.67%

Consensus

Strong Buy

Avg. Price Target

$17.11

Implied Upside

+738.7%

Analysts14incl. previous ratings

Rating Distribution11 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 22, 2026	Initiated	LLeerink Partners	Outperform	$10	+390.2%
Apr 24, 2026	Upgrade	GGoldman	Sell → Neutral	$2.50	+22.5%
Mar 18, 2026	Initiated	TTruist	Buy	$12	+488.2%
Jan 28, 2026	Initiated	BBarclays	Overweight	$20	+880.4%
Jul 10, 2025	Resumed	GGoldman	Sell	$1	-51.0%
Feb 28, 2025	Initiated	WWilliam Blair	Mkt Perform
Jan 08, 2025	Initiated	SStifel	Buy	$18	+782.4%
Nov 12, 2024	Initiated	UUBS	Buy	$26	+1,174.5%
Apr 29, 2024	Downgrade	GGuggenheim	Buy → Neutral
Jan 24, 2024	Initiated	GGoldman	Neutral	$13	+537.3%
Mar 22, 2023	Downgrade	GGoldman	Buy → Neutral	$20 → $6	+194.1%
Dec 01, 2022	Initiated	GGoldman	Buy	$20	+880.4%
Dec 29, 2021	Resumed	JJefferies	Buy	$30	+1,370.6%
Jun 02, 2021	Initiated	HH.C. Wainwright	Buy	$35	+1,615.7%
Feb 11, 2021	Initiated	GGuggenheim	Buy	$36	+1,664.7%
Dec 14, 2020	Initiated	JJefferies	Buy	$25	+1,125.5%
Nov 12, 2020	Reiterated	RB. Riley Securities	Buy	$31 → $28	+1,272.5%
Sep 25, 2020	Initiated	BB. Riley FBR	Buy	$31	+1,419.6%
Aug 14, 2020	Initiated	EEvercore ISI	Outperform
Jul 31, 2020	Initiated	PPiper Sandler	Overweight	$80	+3,821.6%

Oct-27-26 08:00AM	Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution (GlobeNewswire)
Oct-19-26 08:00AM	Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting 2026 (GlobeNewswire)
Sep-23-26 08:00AM	Altimmune to Participate in Stifel Cardiometabolic Forum (GlobeNewswire) -6.45%
Sep-22-26 01:29AM	VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
Sep-03-26 08:00AM	Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
07:03PM	Loading…
Aug-12-26 07:03PM	Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... (GuruFocus.com)
07:30AM	Altimmune Announces Second Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Aug-05-26 08:00AM	Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 (GlobeNewswire)
Aug-03-26 08:00AM	Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH (GlobeNewswire) +5.63%
Jul-29-26 07:00AM	FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimers data (BioPharma Dive)
Jul-28-26 02:42PM	ALT Stock Reverses Early Gains On Positive Alcohol Use Trial But Wall Street, Retail Investors Dismiss Selloff (Stocktwits)
08:33AM	Altimmunes Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint ALT Stock Jumps 10% (Stocktwits)
08:22AM	Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results (InvestorsHub)
07:00AM	Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Jul-13-26 05:10AM	US Research house initiates Solvonis coverage citing differentiated addiction strategy (Proactive)
11:00AM	Loading…
May-28-26 11:00AM	Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026 (GlobeNewswire)
May-27-26 08:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 (GlobeNewswire)
May-13-26 07:01PM	Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ... (GuruFocus.com)
09:29AM	Altimmune shares climb after first-quarter loss beats expectations (ALT) (InvestorsHub)
07:30AM	Altimmune Announces First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
07:15AM	Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 (GlobeNewswire)
May-06-26 07:30AM	Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 (GlobeNewswire) +6.54%
Apr-27-26 07:00AM	Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities (GlobeNewswire)
Apr-22-26 11:25PM	Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities (GlobeNewswire) -16.71%
04:19PM	Altimmune Announces Proposed Underwritten Public Offering of Securities (GlobeNewswire)
Mar-24-26 11:05AM	Anti-Aging Protein Research Takes a Step Forward with Cell Cloning (PR Newswire) -5.81%
Mar-05-26 06:47PM	Altimmune Q4 Earnings Call Highlights (MarketBeat) -17.92%
04:04PM	Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification (GuruFocus.com)
07:00AM	Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates (GlobeNewswire)
07:30AM	Loading…
Mar-02-26 07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-26-26 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 (GlobeNewswire)
Feb-17-26 08:44PM	Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances (Insider Monkey)
Feb-02-26 09:55AM	Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development (Insider Monkey)
Jan-29-26 05:54PM	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.80%
01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-28-26 04:13PM	Altimmune (ALT) Shares Slide On $75 Million Stock Offering (Benzinga) -17.15%
Jan-27-26 09:25PM	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.19%
Jan-23-26 02:06PM	Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly (24/7 Wall St.)
09:40AM	Unusually active option classes on open January 22nd (TipRanks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Jan-05-26 07:30AM	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH (GlobeNewswire) +16.52%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Dec-19-25 06:30AM	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial (GlobeNewswire) -22.77%
Dec-11-25 09:55AM	Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? (Zacks)
Dec-01-25 07:30AM	Altimmune Announces CEO Transition and Succession Plan (GlobeNewswire) -6.27%
Nov-26-25 07:30AM	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-25-25 09:55AM	Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know (Zacks)
Nov-11-25 08:51AM	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-08-25 06:05AM	Altimmune price target lowered to $14 from $15 at Citizens JMP (TipRanks)
Nov-07-25 08:05AM	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 07:00AM	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +5.07%
Nov-05-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 07:30AM	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire)
Oct-20-25 07:30AM	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 08:45AM	Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Sep-30-25 10:52AM	Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALT (Business Wire)
Sep-29-25 07:30AM	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide (GlobeNewswire) -5.25%
Sep-23-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 07:30AM	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer (GlobeNewswire)
Sep-09-25 09:00AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire)
Sep-02-25 08:45AM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Aug-26-25 08:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-25 07:30AM	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
Aug-14-25 04:34PM	Investors in Altimmune, Inc. (ALT): Protect Your Rights - Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
Aug-13-25 04:24PM	Altimmune, Inc. (ALT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
03:07AM	Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... (GuruFocus.com)
Aug-12-25 07:00AM	Altimmune Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) +7.10%
Aug-11-25 07:30AM	Altimmune Board of Directors Appoints Jerry Durso as Chairman (GlobeNewswire)
Aug-05-25 07:30AM	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 (GlobeNewswire)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-09-25 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arbet-Engels Christophe	Chief Medical Officer	Oct 01 '26	Option Exercise	0.00	37,500	0	37,500	Oct 05 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Oct 01 '26	Option Exercise	0.00	14,475	0	54,306	Oct 05 04:05 PM
Richardson Linda M	Chief Commercial Officer	Sep 16 '26	Option Exercise	0.00	24,000	0	24,000	Sep 17 04:05 PM
Durso Jerome Benedict	President and CEO	Aug 13 '26	Buy	2.95	15,000	44,250	62,500	Aug 13 04:05 PM
GILL JOHN	Director	Apr 06 '26	Buy	3.41	9,200	31,350	21,700	Apr 06 04:05 PM
WEAVER GREGORY L	Chief Financial Officer	Apr 01 '26	Buy	3.15	10,000	31,499	38,078	Apr 01 04:05 PM
Durso Jerome Benedict	President and CEO	Apr 01 '26	Buy	3.14	15,000	47,100	47,500	Apr 01 04:05 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 06 '26	Buy	3.54	5,000	17,700	28,078	Mar 09 07:05 AM
Durso Jerome Benedict	President and CEO	Mar 06 '26	Buy	3.54	20,000	70,790	32,500	Mar 09 07:00 AM
Roberts M Scot	Chief Scientific Officer	Feb 02 '26	Option Exercise	0.00	7,775	0	115,153	Feb 03 04:15 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '26	Option Exercise	0.00	9,275	0	104,670	Feb 03 04:15 PM
Garg Vipin K	Director	Jan 30 '26	Option Exercise	0.00	26,775	0	429,225	Feb 02 04:15 PM
Jordt Raymond M	Chief Business Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	69,765	Jan 29 04:15 PM
Garg Vipin K	Director	Jan 27 '26	Option Exercise	0.00	41,200	0	420,348	Jan 29 04:10 PM
Roberts M Scot	Chief Scientific Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	100,143	Jan 29 04:05 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	57,770	Jan 27 07:10 AM
Garg Vipin K	Director	Jan 25 '26	Option Exercise	0.00	42,050	0	397,132	Jan 27 07:05 AM
Roberts M Scot	Chief Scientific Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	88,666	Jan 27 07:00 AM
Pisano Wayne	Director	Jan 08 '26	Buy	4.08	5,000	20,410	13,498	Jan 09 04:10 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '26	Option Exercise	0.00	9,375	0	45,645	Jan 05 04:10 PM
Jorkasky Diane	Director	Dec 29 '25	Buy	3.80	527	2,003	527	Dec 29 04:10 PM
GILL JOHN	Director	Dec 23 '25	Buy	4.10	12,500	51,250	12,500	Dec 23 04:10 PM
Durso Jerome Benedict	Director	Dec 22 '25	Buy	4.13	12,500	51,569	12,500	Dec 22 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Nov 11 '25	Option Exercise	0.00	18,750	0	28,750	Nov 12 04:07 PM

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

ChairmanMr. Jerome Benedict Durso

Chief Scientific OfficerDr. M. Scot Roberts Ph.D.

M.D.Dr. Christophe Arbet-Engels M.B.A.

M.B.A.Mr. Gregory L. Weaver CPA

VPMr. Richard Menziuso

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALT

Altimmune Inc

Upgrade your Finviz experience